Fruquintinib May Edge Ahead in KRAS-Mutant Colorectal Cancer, But No Clear Winner Yet
A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend survival in refractory metastatic ...
Tag: regorafenib
Two-Drug Combo Supercharges Liver Cancer Therapy in Preclinical Study
A preclinical study reports that combining the kinase inhibitor regorafenib with the small-molecule PD-1/PD-L1 inhibitor BMS-1 synergistically suppresses the growth, ...
Two Late-Line Drugs Offer Equal Survival in Metastatic Colorectal Cancer, Landmark Study Finds
A large prospective Japanese study found that late-line treatment sequences beginning with either regorafenib or trifluridine/tipiracil plus bevacizumab yielded comparable ...
Cancer Drug Hand-Foot Syndrome Risks Mapped in Huge FDA Analysis
A sweeping analysis of more than 21,500 FDA adverse event reports has mapped which anticancer drugs most strongly trigger hand-foot ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!